These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20410924)

  • 1. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
    Pardanani A; Lasho TL; Finke CM; Mai M; McClure RF; Tefferi A
    Leukemia; 2010 Jun; 24(6):1146-51. PubMed ID: 20410924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
    Tefferi A; Lasho TL; Abdel-Wahab O; Guglielmelli P; Patel J; Caramazza D; Pieri L; Finke CM; Kilpivaara O; Wadleigh M; Mai M; McClure RF; Gilliland DG; Levine RL; Pardanani A; Vannucchi AM
    Leukemia; 2010 Jul; 24(7):1302-9. PubMed ID: 20508616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
    Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
    Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
    Pasca S; Chifotides HT; Verstovsek S; Bose P
    Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
    Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
    Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.
    Tefferi A; Jimma T; Sulai NH; Lasho TL; Finke CM; Knudson RA; McClure RF; Pardanani A
    Leukemia; 2012 Mar; 26(3):475-80. PubMed ID: 21912393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
    Tefferi A
    Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis.
    Yonal-Hindilerden I; Daglar-Aday A; Hindilerden F; Akadam-Teker B; Yilmaz C; Nalcaci M; Yavuz AS; Sargin D
    J Clin Med Res; 2016 Jan; 8(1):29-39. PubMed ID: 26668680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.
    Chen D; Geyer J; Bagg A; Hasserjian R; Weinberg OK
    Int J Lab Hematol; 2024 Aug; 46(4):687-694. PubMed ID: 38665121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
    Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.
    Rumi E; Harutyunyan A; Elena C; Pietra D; Klampfl T; Bagienski K; Berg T; Casetti I; Pascutto C; Passamonti F; Kralovics R; Cazzola M
    Am J Hematol; 2011 Dec; 86(12):974-9. PubMed ID: 21953568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
    Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
    Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
    Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
    Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
    Pardanani AD; Levine RL; Lasho T; Pikman Y; Mesa RA; Wadleigh M; Steensma DP; Elliott MA; Wolanskyj AP; Hogan WJ; McClure RF; Litzow MR; Gilliland DG; Tefferi A
    Blood; 2006 Nov; 108(10):3472-6. PubMed ID: 16868251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated and blast phase myeloproliferative neoplasms.
    Saliba AN; Gangat N
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.